PubRank

David L Rimm

Author PubWeight™ 239.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005 15.28
2 Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002 8.04
3 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009 7.95
4 X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004 6.22
5 Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006 4.66
6 Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007 4.23
7 Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004 3.64
8 Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005 3.62
9 Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011 2.78
10 GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009 2.77
11 Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004 2.74
12 Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004 2.44
13 A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008 2.43
14 Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 2009 2.41
15 Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011 2.23
16 β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011 2.17
17 Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 2011 1.99
18 Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003 1.96
19 microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov 2012 1.94
20 Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006 1.91
21 Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008 1.89
22 High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007 1.88
23 Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003 1.85
24 Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009 1.83
25 Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004 1.82
26 Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 2004 1.80
27 Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003 1.75
28 Utility of multispectral imaging for nuclear classification of routine clinical histopathology imagery. BMC Cell Biol 2007 1.72
29 Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002 1.69
30 Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006 1.65
31 Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res 2007 1.62
32 In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010 1.62
33 Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2008 1.61
34 Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011 1.56
35 Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011 1.54
36 Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 2010 1.51
37 Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008 1.50
38 Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005 1.49
39 Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007 1.45
40 Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009 1.44
41 Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 2006 1.43
42 Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007 1.42
43 Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005 1.42
44 Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 2012 1.42
45 Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 2004 1.40
46 Translational crossroads for biomarkers. Clin Cancer Res 2005 1.38
47 Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 2003 1.35
48 Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003 1.34
49 Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 2010 1.34
50 Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 2009 1.33
51 Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003 1.31
52 Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 2007 1.31
53 Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS One 2012 1.28
54 High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008 1.26
55 beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004 1.23
56 A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol 2011 1.23
57 Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 2007 1.22
58 Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005 1.22
59 Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 2009 1.21
60 The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007 1.21
61 alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 2004 1.20
62 Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004 1.20
63 Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 2005 1.20
64 Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 2007 1.20
65 Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013 1.19
66 Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011 1.19
67 Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 2004 1.18
68 Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 2012 1.17
69 Fine-needle aspiration of follicular adenoma versus parathyroid adenoma: the utility of multispectral imaging in differentiating lesions with subtle cytomorphologic differences. Cancer 2008 1.16
70 Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol 2009 1.16
71 Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005 1.13
72 High SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS One 2013 1.13
73 Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006 1.12
74 PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 2012 1.11
75 Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008 1.11
76 Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2008 1.10
77 Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005 1.08
78 Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2009 1.08
79 Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003 1.07
80 Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res 2011 1.07
81 Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010 1.07
82 Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 2011 1.07
83 Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer. Am J Pathol 2012 1.06
84 Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 2009 1.06
85 In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab Invest 2012 1.05
86 Direct interaction of the C-terminal domain of alpha-catenin and F-actin is necessary for stabilized cell-cell adhesion. Cell Commun Adhes 2006 1.04
87 Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007 1.04
88 DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiol Biomarkers Prev 2009 1.04
89 Detection of malignancy in cytology specimens using spectral-spatial analysis. Lab Invest 2005 1.04
90 Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene 2005 1.03
91 Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009 1.03
92 Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res 2006 1.03
93 Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Res Treat 2008 1.03
94 Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res 2005 1.02
95 Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006 1.01
96 Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer 2002 1.01
97 A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med 2013 1.01
98 Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 2011 1.00
99 Bimodal population or pathologist artifact? J Clin Oncol 2007 1.00
100 Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009 0.99
101 Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009 0.99
102 Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med 2008 0.99
103 PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc Natl Acad Sci U S A 2010 0.99
104 Automated analysis of tissue microarrays. Methods Mol Biol 2010 0.99
105 Tissue microarrays without cores. Nat Methods 2005 0.98
106 Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes 2011 0.98
107 Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol 2011 0.98
108 Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Hum Pathol 2008 0.98
109 Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 2013 0.97
110 C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res 2009 0.97
111 The value of onsite adequacy assessment of thyroid fine-needle aspirations is a function of operator experience. Cancer 2006 0.96
112 Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res 2003 0.96
113 Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res 2012 0.96
114 Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res 2012 0.96
115 Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Mod Pathol 2012 0.96
116 Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010 0.95
117 Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 2005 0.95
118 Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab 2014 0.94
119 Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod Pathol 2008 0.94
120 The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer 2010 0.93
121 Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 2010 0.92
122 Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma. Diagn Mol Pathol 2006 0.90
123 High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 2009 0.90
124 Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 2007 0.90
125 Definition of a direct extracellular interaction between Met and E-cadherin. Cell Biol Int 2007 0.90
126 Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. Cancer 2011 0.90
127 Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 2012 0.89
128 What are the biggest challenges and opportunities for biorepositories in the next three to five years? Biopreserv Biobank 2010 0.89
129 Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer. Mod Pathol 2005 0.88
130 High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010 0.88
131 Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 2012 0.88
132 Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 2005 0.88
133 Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core? Arch Pathol Lab Med 2010 0.87
134 Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin Cancer Res 2003 0.86
135 High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci 2012 0.86
136 Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Res Treat 2012 0.86
137 Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res 2011 0.86
138 Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. J Biol Chem 2003 0.86
139 Diagnostic classification of urothelial cells in urine cytology specimens using exclusively spectral information. Cancer 2004 0.85
140 ERβ splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Res Treat 2014 0.85
141 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res 2004 0.85
142 The histologic subtype of ovarian tumors affects the detection rate by pelvic washings. Cancer 2004 0.85
143 Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. Breast Cancer Res 2010 0.85
144 Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol Biomarkers Prev 2005 0.85
145 Construction and analysis of multiparameter prognostic models for melanoma outcome. Methods Mol Biol 2014 0.84
146 Immunocytochemical analysis of breast cells obtained by ductal lavage. Cancer 2002 0.84
147 Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray. Clin Colorectal Cancer 2002 0.84
148 In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res 2011 0.83
149 Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One 2013 0.83
150 Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Res Treat 2011 0.83
151 Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res 2010 0.83
152 The function, proteolytic processing, and histopathology of Met in cancer. Adv Cancer Res 2009 0.82
153 Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J 2005 0.82
154 Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array Device. Mol Ther Nucleic Acids 2013 0.82
155 AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Arch Pathol Lab Med 2008 0.82
156 Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. Cancer Inform 2008 0.81
157 Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med 2013 0.81
158 Making every cell like HeLa a giant step for cell culture. Am J Pathol 2011 0.81
159 Quantification of hormone receptors to guide adjuvant therapy choice in early breast cancer: better methods required for improved utility. J Clin Oncol 2011 0.80
160 Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Arch Pathol Lab Med 2016 0.80
161 Novel tyramide-based tyrosinase assay for the detection of melanoma cells in cytological preparations. Diagn Cytopathol 2004 0.80
162 Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. Histochem Cell Biol 2014 0.79
163 Automated objective determination of percentage of malignant nuclei for mutation testing. Appl Immunohistochem Mol Morphol 2014 0.79
164 Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One 2013 0.78
165 Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol 2013 0.78
166 A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med 2013 0.78
167 Cruella: developing a scalable tissue microarray data management system. Arch Pathol Lab Med 2006 0.77
168 Quantitative examination of mechanophysical tumor cell enrichment in fine-needle aspiration specimens. Cancer 2002 0.77
169 TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol 2013 0.75
170 What's in a name? Arch Pathol Lab Med 2006 0.75
171 p53 mutations as tumor markers in fine needle aspirates of palpable breast masses. Acta Cytol 2002 0.75
172 Breast cancer misclassification: a major obstacle to treatment? Womens Health (Lond Engl) 2011 0.75
173 Spatial spectral imaging as an adjunct to the Bethesda classification of thyroid fine-needle aspiration specimens. Cancer Cytopathol 2012 0.75
174 Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary: cutting edge or already obsolete? Cancer Cytopathol 2012 0.75
175 Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. Cancer Epidemiol Biomarkers Prev 2006 0.75